SpeciGen

SpeciGen is a clinical-stage biotechnology company specializing in the development of T-cell receptor engineered T-cell (TCR-T) therapies for the treatment of solid tumors. The company leverages a proprietary platform to identify and validate high-affinity TCRs that specifically target tumor-associated antigens and viral antigens. Its lead candidate, SG-101, is a TCR-T therapy designed to treat Hepatitis B virus (HBV)-related hepatocellular carcinoma, a major unmet medical need in global oncology. SpeciGen's pipeline also includes programs targeting other well-characterized antigens such as NY-ESO-1 for various solid malignancies. The company aims to overcome the immunosuppressive nature of the solid tumor microenvironment to deliver durable clinical responses.